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Genotypic and phenotypic tolerance was studied in penicillin treatment of experimental endocar-
ditis due to nontolerant and tolerant Streptococcus gordonii and to their backcross transformants.
The organisms were matched for in vitro and in vivo growth rates. Rats with aortic endocarditis
were treated for 3 or 5 days, starting 12, 24, or 48 h after inoculation. When started at 12 h, during
fast intravegetation growth, 3 days of treatment cured 80% of the nontolerant parent compared
with <30% of the tolerant derivative (P < .005). When started at 24 or 48 h and if intravegetation
growth had reached a plateau, 3 days of treatment failed against both bacteria. However, a significant
difference between the 2 organisms was restored when treatment was extended to 5 days. Thus,
genotypic tolerance conferred a survival advantage in both fast- and slow-growing bacteria, demon-
strating that the in vitro-defined tolerant phenotype also carried the risk of treatment failure in
vivo.
Bacteria have developed at least two mechanisms that enable
them to survive the lethal effect of .B-lactam antibiotics and
other bactericidal drugs: antibiotic resistance and antibiotic tol-
erance. Resistant bacteria can grow in the presence of increased
concentrations of antibiotics, resulting in increased MICs.
However, beyond the elevated MICs, resistant bacteria remain
sensitive to the bactericidal effects of the drugs. In contrast,
tolerant bacteria are sensitive to the bacteriostatic effect of
antibiotics (i.e., their MIC is unchanged) but have a drastically
decreased susceptibility to drug-induced killing [1,2]. In other
words, bactericidal agents behave like bacteriostatic drugs
against tolerant bacteria.
Two types of tolerance have been described: genotypic and
phenotypic. Genotypic tolerance is conferred by so-called sur-
vival mutations, is expressed during the whole bacterial growth
cycle, and can be transmitted both vertically to the bacterial
progeny and horizontally by DNA transformation to other cells,
as shown in Streptococcus pneumoniae [3] and Streptococcus
gordonii (this work). Of interest, tolerance mutations are not
genetically linked to resistance mutations in these 2 organisms
[4] (unpublished observation). Phenotypic tolerance is charac-
terized by the well-known fact that slow-growing bacteria have
increased resistance to the bactericidal effect ofcell-wall inhibi-
tors [5]. Phenotypic tolerance is only expressed during slow
bacterial division, but it is a property of any bacterial strain.
Antibiotic resistance is clinically important because it can
lead to treatment failure. Tolerance also has caused treatment
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failure in several animal studies, but its clinical impact is more
difficult to assess. First, although tolerance is an in vitro mea-
surement of the ability ofbacteria to survive antibiotic-induced
killing, it still lacks a clear-cut definition as well as standardized
procedures for its determination in the laboratory [6, 7]. Sec-
ond, studies that have investigated the clinical implication of
tolerance are retrospective, often lack adequate control groups,
and sometimes provide controversial results [2, 8]. Third, most
animal studies to date suffer from potential bias as they have
compared unrelated pairs of tolerant and nontolerant bacteria
that may have been different in parameters other than tolerance
per se [9-13]. Only Voom and colleagues [14, 15] and Meeson
et al. [16] studied related pairs of nontolerant and tolerant
staphylococci and streptococci. They showed that tolerance
impaired therapy with .B-lactam drugs [14, 16] but not with
peptide antibiotics [15]. Finally, none of these studies investi-
gated the impact of phenotypic tolerance (i.e., slow-growing
bacteria in the experimental setting), the role of which was
recently highlighted in an experimental model of endocarditis
caused by Staphylococcus epidermidis [17]. Therefore, it is
difficult to draw definitive conclusions from currently available
data.
In the present study, we systematically investigated the role
of genotypic and phenotypic tolerance in penicillin treatment
of experimental endocarditis due to S. gordonii. Rats with cath-
eter-induced aortic vegetations were infected either with the
penicillin-nontolerant parent strain or with a penicillin-tolerant
derivative produced by cyclic exposure of the parent cells to
penicillin in vitro. Antibiotic therapy was started at various
times after inoculation, either when bacteria were actively
growing in the cardiac vegetations or when they had reached
a plateau and displayed phenotypic tolerance. Eventually, the
reliability of the system was confirmed by use of an isogenic
pair of nontolerant-tolerant S. gordonii transformants that were
constructed by backcrossing chromosomal DNA of either a
nontolerant or a tolerant derivative into the parent cells.
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Materials and Methods
Microorganisms, growth conditions, and antibacterial agents.
We used a spontaneous streptomycin-resistant mutant (StR) of S.
gordonii Challis (formerly Streptococcus sanguis) [18], which is
susceptible to penicillin-induced killing (Tol- phenotype), and a
penicillin-tolerant (Tol+ phenotype) derivative of this bacterium
(see below) in the experiments. Unless otherwise stated, bacteria
were grown at 37°C in brain-heart infusion broth (BHI; Difco
Laboratories, Detroit) without aeration or on Columbia agar (Bec-
ton Dickinson Microbiology Systems, Cockeysville, MD) supple-
mented with 3% blood. Culture growth was assessed by spectro-
photometer (Sequoia-Turner, Mountainville, CA) for changes in
optical densities (wavelength of 620 nm; OD620) and by viable cell
counts. Bacterial stocks were frozen in BHI containing 10% (voll
vol) glycerol and stored at -70°C. We purchased penicillin G and
procaine penicillin from Hoechst-Pharma (Zurich) and streptomy-
cin from Sigma (St. Louis).
Antibiotic susceptibility and time-kill curves. The MICs of the
test antibiotics were determined by a standard macrodilution
method [19] in BHI using a 105_106 cfu/mL overnight culture of
bacteria as inoculum. The MICs were defined as the lowest antibi-
otic concentrations inhibiting visible bacterial growth after 24 h of
incubation. The MBCs ofthe drugs were measured by subculturing
O.Ol-mL samples from the MIC tubes showing no turbidity onto
blood agar supplemented with 2000 U/rnL penicillinase (Bacto-
Penase concentrate; Difco) to minimize the effect of antibiotic
carry-over on the plates [6]. MBCs were determined after incuba-
tion for 48 h at 37°C and defined as the lowest antibiotic concentra-
tions resulting in ;:;,99.9% killing of the original inoculum.
Time-kill curves were determined by adding 20x the MIC of
penicillin (final concentration) to bacterial cultures at various times
during the logarithmic and the early stationary phase of growth.
In brief, tubes containing fresh prewarmed (at 37°C) medium were
inoculated with 0.1 mL ofan overnight bacterial culture and further
incubated at 37°C without aeration. Samples of the cultures were
removed at various times before and after the addition ofpenicillin,
serially diluted, and plated on penicillinase-containing agar plates
for colony counts.
Selection of penicillin-tolerant derivatives of S. gordonii and
DNA-backcross experiments. Derivatives of S. gordonii that
were tolerant to the bactericidal effect of penicillin were obtained
by cyclic exposure of parent cultures to high concentrations of
penicillin as previously described [20]. Nonmutagenized cultures
of a spontaneous StR mutant of S. gordonii were grown to the
midlogarithmic phase (OD620 ~0.2) in 10 mL of BHI supple-
mented with 100 mg/L streptomycin and then treated with 2 mg/
L penicillin (i.e., 500x the MIC, final concentration) for 18-20
h at 37°C. This concentration was chosen because it is easily
reached in human serum during standard penicillin therapy (see
Results). Streptomycin was constantly kept in the medium to avoid
contamination during the enrichment cycles. The cells were then
washed three times by centrifugation (6000 g for 15 min) and
resuspended in fresh medium, and the survivors were allowed to
regrow overnight in penicillin-free BHI. After eight such enrich-
ment cycles, single colonies were further characterized for in vitro
properties of antibiotic susceptibility, tolerance, and stability of
the tolerant phenotype. Tolerance stability was tested by serial
passages ofthe derivatives (up to 35 generation times) in antibiotic-
free liquid cultures.
In certain experiments, competent cells of the original strepto-
mycin-susceptible S. gordonii strain were transformed with either
chromosomal DNA of the StR parent strain described above or
with DNA of one of its penicillin-tolerant derivatives [18]. Selec-
tion was for the acquisition of the StR marker (on agar plates
containing 200 mg/L streptomycin) either alone, to determine the
transformation frequency of this known marker, or for the StR
marker plus the tolerant phenotype as described [3]. The behavior
of these backcross transformants was then tested both in vitro and
in vivo in the experimental endocarditis model.
Rat model ofexperimental endocarditis. Sterile aortic vegeta-
tions were produced in female Wistar rats (180-200 g) as pre-
viously described [21]. Bacterial endocarditis was induced 48 h
later by intravenous (iv) challenge with 0.5 rnL of saline containing
various sizes of bacterial inocula. Inoculum sizes were controlled
in parallel by plating serial dilutions of the bacterial suspensions
injected into animals on agar plates. Infection was assessed at
various times after bacterial challenge. The rats were killed in a
100% CO2 atmosphere, and blood was immediately drawn for
semiquantitative cultures. The cardiac vegetation and spleen were
dissected, weighed, homogenized in 1 mL of saline, serially di-
luted, and plated for viable colony counts. Colonies growing on
the plates were enumerated after 48 h of incubation at 37°C. The
dilution technique enabled detection of ;:;,2 10glO cfu/g of tissue.
Vegetations with negative cultures were given a value of 2 10glO
cfu/g in subsequent calculations for statistical analysis.
Assessing the bacterial infectivity in vivo. To determine
whether penicillin-tolerant derivatives ofS. gordonii and the parent
bacteria could provoke experimental endocarditis, we determined
both the minimum size of inoculum producing endocarditis in 90%
of the rats (ID90) and the rate of bacterial growth in situ in the
vegetation. The ID90 was determined by challenging groups of 8-
10 rats with various inoculum sizes (103-106 cfu) of each test
organism and measuring the rates and intensity of valvular infec-
tions 24 h later. To establish the kinetics of bacterial growth in
the vegetation, a large group ofanimals was challenged with 100X
the ID90 of the test organisms, and the progressive increase in
bacterial densities in the vegetations was followed by killing sub-
groups of rats at various times after inoculation. Vegetations and
spleens were processed as described above.
Penicillin treatment of experimental endocarditis. Penicillin
treatment was started 12, 24, or 48 h after inoculation of the rats
with 100X the ID9o• Groups of animals infected with either test
organism were treated for 3 or 5 days with procaine penicillin
(300,000 U/kg) given subcutaneously twice a day. This regimen
produced peak and trough antibiotic levels in the rat sera that
approximated drug concentrations in humans during iv penicillin
therapy (see Results). Untreated control rats were sacrificed at the
start of therapy to determine both the rate and the severity of
infection. Treated animals were killed 24 h after the last antibiotic
dose, when no residual antibiotic activity was detected in sera.
Rats that died during therapy were taken into account for vegeta-
tion bacterial densities only if they had received treatment for ;:;,2
days. In addition, bacteria recovered from infected valves were
retested in vitro to establish the stability of the nontolerant and
tolerant phenotypes of the test strains.
Determination ofserum concentrations ofpenicillin, serum in-
hibitory titers (SITs), and serum bactericidal titers (SBTs) in rats.
Penicillin concentrations in sera were determined in groups of 3-
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Figure 1. Penicillin-induced killing of nontolerant (Tol-) S. gordonii parent strain (left) and its penicillin-tolerant Tol+ I derivative (right).
Broth cultures of organisms were treated with 20X MIC of penicillin (final concentration) during logarithmic or early stationary phase of
growth (arrows), and viable cells in cultures were followed over time.
6 infected rats at various times before and after antibiotic adminis-
tration. Blood samples were drawn from the retroorbital sinus, and
antibiotic concentrations were measured by bioassay using Bacillus
subtilis ATCC 6633 as an indicator organism. Antibiotic standards
were dissolved in pooled rat serum. The assay limit of detection
was 0.04 mg/L. The linearity of the standard curve was assessed
by a regression coefficient of r = .99, and the intra- and interplate
coefficient of variation of the assay was consistently < 10%.
The SITs and the SBTs were determined at peak (1 h) and
trough (12 h) antibiotic concentrations by a standard method [22],
using an inoculum of 105-1 06 cfulmL and pooled rat serum con-
taining 50% BHI as a diluent. The SIT was defined as the largest
dilution of serum inhibiting visible bacterial growth, and the SBT
was defined as the largest dilution killing ;:;99.9% of the original
inoculum after 24 h of incubation at 37°C.
Statistical analyses. We used Fisher's exact test to compare
the incidence of valvular infection. Differences between bacterial
densities of various treatment groups were compared by the non-
parametric Mann-Whitney Wilcoxon unpaired test or one-way
analysis of variance when adequate. All significant (P ~ .05)
differences were determined by the two-tailed test.
Results
In vitro characterization of the nontolerant parent S. gor-
donii and the tolerant derivative Tor1. The MIC ofpenicillin
for the Tol- parent S. gordonii was 0.004 mg/L. Penicillin
treatment (with 20x the MIC) of logarithmically growing cul-
tures of this strain resulted in a loss of viable counts of 3-4
10glO cfu/mL in 24 h (figure 1). This loss of viability was
reduced to 1-2 loglo cfu/mL after eight enrichment cycles of
the parent culture with penicillin [23]. The bacteria were then
plated, and single colonies were selected and regrown in sepa-
rate cultures for further characterization. One of these, Tol+1,
was used in the present experiments. Tol+l had an unchanged
MIC of penicillin (0.004 mg/L) compared with the wild type
parent and grew at the same rate in broth cultures (figure 1).
However, Tol+l had a greatly increased MBC of penicillin
(;:; 128 mg/L vs. 0.008 mg/L for the parent) and complied with
the definition of penicillin-tolerance assessed by an MBC-to-
MIC ratio ;:;32 [24] (ratio ~3200 and 2 for Tol+l and the
parent strain, respectively). The Tol+ 1 derivative was also sta-
ble. It did not lose the tolerance phenotype for up to 35 genera-
tion times in penicillin-free medium.
Figure 1 shows the time-kill curves of both the Tol- parent
and the Tol+l derivative exposed to 20x the MIC ofpenicillin.
When added to cultures in the logarithmic phase of growth,
penicillin killed the Tol- parent cells but did not kill the Tol+l
derivative. In contrast, when added to the cultures in the early
stationary phase ofgrowth, penicillin failed to kill either organ-
ism because of phenotypic tolerance. These results clearly dis-
sociated the genotypic and phenotypic tolerance traits of the 2
organisms in vitro and established a basis for further testing
the 2 bacteria in vivo.
In vivo infectivity and bacterial growth in vegetations ofthe
Tor parent and the Tor1 derivative. The 2 organisms had
similar ID90 (i.e., 105 cfu) in the rat model of experimental
endocarditis. This indicated that the Tol+l derivative was not
affected in its ability to colonize damaged valves and induce
infectious endocarditis. Moreover, in experiments using inocula
of 100x the ID9o, both the Tol- parent and the Tol+l derivative
grew at similar rates in the vegetations after establishing infec-
tion (figure 2, upper). Blood cultures were positive in >90%
of the animals, regardless of the infecting organism. Median
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Figure 2. Intravegetation growth (upper)
and outcome of 3 and 5 days penicillin treat-
ment of experimental endocarditis caused by
nontolerant (Tol-) S. gordonii parent strain or
by tolerant derivative Tol+l (lower). Each dot
in upper panel represents bacterial density in
vegetation of separate control rats sacrificed at
onset of therapy. Columns (lower panel) show
% of infected vegetations after 3 or 5 days of
penicillin therapy. Numbers of animals in each
treatment group are noted at column bottoms
(n=). MBD is median bacterial density ofveg-
etations. * P < .005 vs. Tol+1 derivative.
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levels of bacteremia increased from 16 cfulmL (range, 0-54)
and 13 cfulmL (range, 0-43) in 7-12 animals infected with
the Tol- parent or the Tol+1 derivative, respectively, 12 h after
inoculation to 1000 cfulmL (range, 0-1000) for both organisms
after 48 h (P > .05). Bacterial densities in the spleens also
increased in parallel over time from 3.82 ± 0.56 and 3.84 ±
0.44 (mean loglo cfulg of tissue in 7-12 animals infected with
the Tol- parent or the Tol+ 1 derivative, respectively) 12 h after
inoculation to 4.37 ± 0.35 and 4.06 ± 0.64, respectively, after
48 h (P > .05). Therefore, both the Tol- parent and its Tol+l
derivative behaved alike in several important aspects of experi-
mental endocarditis: the establishment of valvular infection,
the in situ growth rates in the vegetation, the levels of bacter-
emia, and the colonization of target organs such as the spleen.
These similarities allowed the further comparison of these 2
organisms in therapeutic experiments with penicillin.
Penicillin concentrations in the serum of rats: SITs and
SETs. Peak and trough concentrations of penicillin in rat sera
during antibiotic therapy were (mean ± SD of 10-13 rats)
12.27 ± 4.16 mgIL at 1 h and 5.83 ± 3.32 mgIL at 12 h.
These concentrations were within the range ofpenicillin levels
obtained in humans: Peak serum concentrations can reach .....,60
mg/L during iv therapy [25]. At peak serum concentrations,
the SITs/SBTs of the rat sera were ;:::1:25611:128 for the Tol-
parent and ;::: 1:256/none for the Tol+1 derivative. At trough
levels, these values were 1:256/1 :32 for the Tol- and 1: 128/
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done in which the original streptomycin-susceptible S. gor-
donii strain was transformed either with chromosomal DNA
ofthe Tol- but streptomycin-resistant parent strain described
above or with DNA of its Tol+1 derivative, which also car-
ried the StR marker.
The frequency of transformation to StR was 10-2-10-3 •
Cultures of competent cells treated with DNA of the Tol+1
derivative and subsequently cycled with penicillin consis-
tently converted to the tolerant phenotype after 2 or 3 pas-
sages. In contrast, cultures treated with the control DNA
remained sensitive to penicillin-induced killing for more
than four penicillin-enrichment cycles. When tested in vitro,
both types of transformants had characteristics identical to
their DNA donor for growth rates and penicillin susceptibil-
ity (data not shown). Moreover, the infectivity of these trans-
formants in rats with aortic vegetations were similar to their
parent strains, and they produced the same response patterns
to penicillin treatment as the parent organisms in experimen-
tal endocarditis (figure 3). Penicillin therapy was started 12
h after inoculation in this set of experiments. These results
support the reliability of the experimental system described.
Figure 3. Results of 3 days penicillin treatment of experimental
endocarditis caused by nontolerant (Tor) parent and tolerant deriva-
tive (Tol+) backcross transformants of S. gordonii. Treatment was
started 12 h after bacterial challenge. Each dot represents bacterial
density in vegetation of separated rats sacrificed at onset (controls)
or after 3 days of therapy. Bars in columns indicate median values
of vegetation bacterial densities. * P < .005 vs. Tol+l derivative.
none for the Tol+1 strain. Thus, the 2 organisms were similarly
susceptible to growth inhibition by sera, but only the Tol-
parent was sensitive to serum-induced killing (the Tol+ 1 deriv-
ative survived this treatment). This shows that the tolerant
phenotype ofTol+1 was preserved when tested in the presence
of serum.
Penicillin treatment of experimental endocarditis. Figure
2 (lower) shows results of two series of experiments during
which therapy was given for 3 and 5 days (left and right panels,
respectively). When treatment was started 12 h after inoculation
during fast intravegetation growth (figure 2, upper), 3 days of
penicillin successfully treated 80% of rats infected with the
Tol- parent strain. On the contrary, only 30% ofrats inoculated
with the Tol+1 derivative had sterile vegetation cultures (P <
.005), indicating that genotypic tolerance had a strong impact
on therapeutic success in this particular experimental setting.
Yet, when the 3-day therapy regimen was started 24 or 48 h
after inoculation, the difference in outcome progressively
shrank, as bacterial growth in the vegetation came to a halt
and infections due to the Tol- parent became more difficult to
eradicate. In this case, the effect of genotypic tolerance was
masked by the effect ofphenotypic tolerance in a manner remi-
niscent of that observed in in vitro time-kill curves (see figure
1). This observation raised the question as to whether genotypic
tolerance might still confer a survival advantage during penicil-
lin treatment of slow-growing bacteria or whether its beneficial
effect was limited to logarithmically growing bacteria.
To address this question, we did a series of experiments in
which rats with late onset of therapy (at 48 h) were treated
with penicillin for 5 days instead of 3 days. Figure 2 (lower
right panel) shows the results of these studies. The prolonged
treatment (5 days) restored a statistically significant difference
between the 2 treatment groups. Indeed, endocarditis due to
the Tol+1 derivative was again more difficult to treat than
infections due to the Tol- parent strain (P < .05). Thus, geno-
typic tolerance could adversely affect the success of therapy
in both early and late treatment onset, provided that prolonged
antibiotic treatment enabled detection of the difference.
It is noteworthy that in all of the experiments, bacteria recov-
ered from infected valves retained their original phenotype
regarding penicillin tolerance. Moreover, mortality during ther-
apy was equally distributed in both Tol-- and Tol+1-infected
rats. Overall, ~30% of animals (27 in the Tol- and 30 in the
Tol+1 group) died in each group. Of these, 12% (11 and 12 in
each group, respectively) died after 2 days of therapy. These
animals were taken into account for vegetation bacterial titers
and did not alter the results of the experiments.
Infection due to Tol- and Tol+ transformants ofthe parent
S. gordonii strain. It was important to establish whether
the in vivo difference observed between the Tol- parent and
the Tol+1 derivative was indeed due to tolerance mutations
rather than to unrelated mutations that might have arisen
during the eight penicillin cycles of the original enrichment
procedures. For this purpose, backcross experiments were
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Discussion
Our results clearly show that the in vitro-defined phenome-
non of antibiotic tolerance is also relevant in vivo, as it may
result in treatment failure of experimental endocarditis. The
observation is important because it may have clinical relevance.
Indeed, tolerant derivatives obtained by cyclic exposure ofbac-
teria to antibiotics reflect a kind of antibiotic pressure that
exists in the clinical environment [20]. In addition, the tolerant
derivatives used in the present experiments and in previous
studies that used other types of organisms [14-16] arose from
nonmutagenized bacterial cultures, suggesting that such toler-
ant organisms might also be selected during antibiotic treatment
in humans or animals.
The model of experimental endocarditis is particularly well
suited for the investigation of antibiotic tolerance, because it
tests the bactericidal effect of antimicrobial drugs in the
absence ofhelping host defenses [26], except perhaps for plate-
let-derived microbicidal proteins [27]. On the other hand, the
therapeutic success of a given drug also depends on such antibi-
otic-independent factors as the age of the vegetation [28], the
rate ofbacterial growth in situ at the time of treatment initiation
[17], and pathogenic determinants, such as the production of
exopolysaccharides by the bacteria [29]. Since these parameters
can interfere with the outcome of therapy, they must be care-
fully matched before definitive conclusions can be drawn from
therapeutic experiments that compare nontolerant with tolerant
microorganisms.
In the present experiments, the in vitro and in vivo character-
istics of the pair of related strains were carefully matched
before their behavior was tested in the rats. The results showed
that genotypic tolerance greatly decreased the success of peni-
cillin in early treatment onset. The observation was made both
with the original pair of nontolerant parent and Tol+l strains
and with the backcross-transformants of these organisms. This
provided support for a specific role of tolerance mutations in
treatment failure of early valvular infection. At a later stage,
however, the effect of genotypic tolerance became masked by
phenotypic tolerance leading to questions of the true impor-
tance of genotypic tolerance in the outcome of clinical infec-
tions. Indeed, slow-growing bacteria (i.e., phenotypically toler-
ant cells) are likely to be highly predominant at the treatment
onset ofhuman infections [30] and hence in "slow" endocardi-
tis due to viridans streptococci. In this situation, the predomi-
nant effect of phenotypic tolerance might outweigh genotypic
tolerance, leveling the latter to a mere laboratory curiosity. In
the present experiments, however, when treatment was ex-
tended to 5 days, the genotypic tolerance could still confer a
survival advantage to slow-growing bacteria and contribute to
treatment failure when therapy initiation was delayed. These
results confirm previous experiments that showed the adverse
effect of tolerance on therapy, using related tolerant and nontol-
erant bacteria [14, 16]. In addition, they further demonstrate
that the detrimental effect on antibiotic treatment conferred by
tolerance mutation(s) is maintained after DNA backcross of
these mutations in wild type strains and when slow-growing
bacteria express so-called phenotypic tolerance.
The question arises then as to whether existing antibiotic
regimens against infectious endocarditis might overcome (3-
lactam tolerance in vitro and in vivo. In time-kill experiments,
the combination of penicillin with gentamicin successfully
killed both the Tol- parent and the Tol+l mutant to a similar
extent in vitro (loss of viability >4 10glO cfulmL after 24 h of
antibiotic treatment; data not shown), suggesting that this drug
association might be effective in vivo as well. Indeed, Voom
et al. [14] showed that while treatment with cloxacillin alone
failed against experimental endocarditis due to tolerant staphy-
lococci, the combination of cloxacillin with gentamicin could
restore therapeutic efficacy. Using the same experimental
model, these authors also showed that other classes of antibiot-
ics (i.e., glycopeptides and lipopeptides alone or combined
with rifampin) were equally active against both tolerant and
nontolerant staphylococci in vivo [15]. Thus, from an experi-
mental point of view, therapeutic regimens effective against
tolerant bacteria might exist in the current armamentarium of
antibacterial agents.
Taken together, the present results underscore the relative
importance of genotypic and phenotypic tolerance in penicillin
treatment of experimental streptococcal endocarditis and pro-
vide a rationale for the interpretation of some controversial
results reported in the literature. This revives the suggested,
but incompletely solved, role of tolerant bacteria in treatment
ofhuman endocarditis and is a reminder that bactericidal antibi-
otics are more effective than nonbactericidal drugs in this dis-
ease. It is possible that patients infected with tolerant bacteria
respond less well than those infected with nontolerant bacteria
only during a limited window in the early course of therapy.
On the other hand, patients infected with tolerant organisms
might also experience relapse after short-course treatment.
While these issues have yet to be solved, the present experimen-
tal data underline the potential adverse role of tolerance in
vivo.
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